0.03
+0(+0.00%)
Currency In CAD
Address
#21-1344 Summer Street
Halifax, NS B3H 0A8
Canada
Phone
902 442 4655
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
June 25, 2019
| Name | Title | Pay | Year Born |
| Dr. Donald D. Cilla Jr., M.B.A., Pharmd | Chief Executive Officer, President & Director | 714,942 | N/A |
| Mr. Arthur Baran | Director of New Product Development | 336,570 | N/A |
| Dr. Carl Gelhaus Ph.D. | Director of Non-Clinical Research | 351,456 | N/A |
| Mr. Kenneth G. Howling | Acting Chief Financial Officer | 550,847 | N/A |
| Dr. Gary S. Nabors Ph.D. | Chief Development Officer | 604,881 | N/A |
| Jenna McNeil | Corporate Affairs & Communications Manager | 0 | N/A |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.